News for Bio-Techne Corporation (T1CH34.SA)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

PR NewswireMINNEAPOLIS, Feb. 18, 2025 MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative li

Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ETCompany ParticipantsDavid Clair - Vice President-Investor...

Bio-Techne Corporation (TECH) stock climbs as its Q2 FY25 results exceed Wall Street estimates amid recovery in the biopharma end market. Read more here.

Bio-Techne Corp (TECH), in collaboration with ScaleReady, Wilson Wolf Manufacturing, and CellReady, announced on January 21, 2025, that BrainChild Bio has been

PR NewswireMINNEAPOLIS, Jan. 21, 2025 MINNEAPOLIS, Jan. 21, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will

PR NewswireMINNEAPOLIS, Jan. 7, 2025 MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on a

PR NewswireMINNEAPOLIS, Dec. 12, 2024 MINNEAPOLIS, Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company prov

PR NewswireMINNEAPOLIS, Nov. 27, 2024 MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman,

PR NewswireMINNEAPOLIS, Nov. 20, 2024 MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company prov

BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH

Bio-Techne Corporation (TECH) has announced a significant update regarding its executive compensation strategy. On October 30, 2024, the company's Compensatio

Earnings call: Bio-Techne reports steady growth in Q1 FY2025

Bio-Techne shares target raised, outperform on strong Q1 results

New-age Vaccines Warrant Wide Applicability of Cell Culture! FMI Predicts Favorable Forecast Period for Key Players Despite Waning CAGR. ...

The Global Biopreservation Market Size was Valued at USD 2.7 Billion in 2023 and the Worldwide Biopreservation Market Size is Expected to Reach USD 19.8...

Baron Asset Fund appreciated 6.00% (inst. shares) in the Q1 2024, trailing the Russell Midcap Growth Index by 350 basis points. Click here to read more.

Loading... Loading... Shares of Advanced Micro Devices, Inc. AMD fell sharply during Wednesday's session as the company reported first-quarter results and issu...

According to a recently released Fact.MR analysis, the global market for Cell Treatment Technologies is expected to generate US$ 4.5 billion in revenue in 2022 and is predicted to expand at a CAGR of…